ライフサイエンスコーパス: photodynamic therapy

1 oxaliplatin chemotherapy, radiotherapy, and photodynamic therapy.

2 itor, sensitizes xenotransplanted tumours to photodynamic therapy.

3 role of singlet oxygen and (1)O2 carriers in photodynamic therapy.

4 as effective and well-tolerated as daylight photodynamic therapy.

5 VEGF) interventions, dietary supplements, or photodynamic therapy.

6 econtouring, and antitumor and antimicrobial photodynamic therapy.

7 sensitizers for photocontrolled-delivery and photodynamic therapy.

8 erved between added reovirus before or after photodynamic therapy.

9 a history of choroidal neovascularization or photodynamic therapy.

10 orescence probes, as well as sensitizers for photodynamic therapy.

11 al wastewater treatment, photochemistry, and photodynamic therapy.

12 oninvasive optical imaging, optogenetics and photodynamic therapy.

13 ch as imaging combined with drug delivery or photodynamic therapy.

14 r photocoagulation, CyberKnife radiation, or photodynamic therapy.

15 therapy, hyper- or hypothermic therapy, and photodynamic therapy.

16 s, which makes them potentially suitable for photodynamic therapy.

17 s in photothermal therapy, chemotherapy, and photodynamic therapy.

18 lation of photosensitizer drugs in tumors in photodynamic therapy.

19 for light-triggered biological reactions and photodynamic therapy.

20 n of disease and any previous treatment with photodynamic therapy.

21 ential as photosensitizers for metal-organic photodynamic therapy.

22 topical or injection interferon alfa-2b, and photodynamic therapy.

23 adverse effects, and cost, limit the use of photodynamic therapy.

24 itization, a limitation often encountered in photodynamic therapy.

25 ancer-killing techniques of photothermal and photodynamic therapy.

26 Ir1-HSA are highly favorable properties for photodynamic therapy.

27 enhanced imaging, or phototoxic for improved photodynamic therapy.

28 ong candidate photosensitizer for anticancer photodynamic therapy.

29 poxic tumours are a major problem for cancer photodynamic therapy.

30 umors without relapse by taking advantage of photodynamic therapy.

31 new venues to combat current limitations of photodynamic therapy.

32 ehicles to encapsulate a photosensitizer for photodynamic therapy.

33 ith multiple morphologies and application in photodynamic therapy.

34 alfa-2b (0% vs 1%), cryotherapy (0% vs 3%), photodynamic therapy (0% vs 1%), excisional biopsy and c

35 therapy and the other half treated with AWL photodynamic therapy 1 week apart and randomly allocated

36 n nonmelanoma skin cancer were uncertain for photodynamic therapy (3 trials, 93 participants, risk ra

37 randomly assigned (1:1) to vascular-targeted photodynamic therapy (4 mg/kg padeliporfin intravenously

38 Vascular-targeted photodynamic therapy, a novel tissue-preserving treatmen

39 ing oxidant production by transition metals, photodynamic therapy, activated macrophages, and platele

40 l prodrug valacyclovir and the peptide-based photodynamic therapy agent, 5-aminolevulinic acid.

41 bial and antiviral agents, anticancer drugs, photodynamic therapy agents, radiotherapy agents and bio

42 or 0.5 mg), sham injections plus verteporfin photodynamic therapy (ANCHOR), or sham injections alone

43 y assigned 206 patients to vascular-targeted photodynamic therapy and 207 patients to active surveill

44 e findings may help to alleviate pain during photodynamic therapy and also allow for disease modifica

45 mes were after vs before the introduction of photodynamic therapy and anti-vascular endothelial growt

46 Photodynamic therapy and anti-VEGF drug development occu

47 ffectiveness and adverse effects of daylight photodynamic therapy and artificial white light (AWL) LE

48 e optogenetic control over neurons, targeted photodynamic therapy and deep tissue imaging.

49 photodynamic agent that can be used for both photodynamic therapy and image-guided surgery, allowing

50 By chemotherapy, photodynamic therapy and immunotherapy gathering, the tr

51 ence for technologies including bio-imaging, photodynamic therapy and organic light-emitting diodes.

52 ies based on oxygen free radicals, including photodynamic therapy and radiotherapy, have emerged as p

53 The combination of photodynamic therapy and sonodynamic therapy both in vit

54 The combination of photodynamic therapy and sonodynamic therapy strongly af

55 ad half of their scalp treated with daylight photodynamic therapy and the other half treated with AWL

56 diagnostics and analytics, photothermal and photodynamic therapies, and delivery of target molecules

57 emonstrates a highly promising new agent for photodynamic therapy, and attracts attention to photosta

58 peutics and biologics, chemotherapeutics and photodynamic therapy, and chemotherapeutics and radiothe

59 re interesting for model enzymes, catalysis, photodynamic therapy, and electron transfer.

60 mor hypoxia for enhancement of chemotherapy, photodynamic therapy, and immunotherapy, either individu

61 al in coordination chemistry, anion sensing, photodynamic therapy, and optoelectronics.

62 ns, including light-triggered drug delivery, photodynamic therapy, and photocatalysis.

63 plications, in particular, for optogenetics, photodynamic therapy, and photochemistry.

64 ch terms solar keratosis, actinic keratosis, photodynamic therapy, and photochemotherapy.

65 ts of repeated applications of antimicrobial photodynamic therapy (aPDT) adjunctive to scaling and ro

66 ficacy of multiple sessions of antimicrobial photodynamic therapy (aPDT) as an adjunct to surgical pe

67 im of this study is to compare antimicrobial photodynamic therapy (aPDT) as an adjunctive therapy to

68 Antimicrobial photodynamic therapy (aPDT) is an emerging treatment for

69 a promising photosensitizer in antimicrobial photodynamic therapy (aPDT).

70 low-intensity laser (LIL); 2) antimicrobial photodynamic therapy (aPDT); or 3) toluidine blue O (TBO

71 ent singlet-oxygen generation with potential photodynamic therapy application as demonstrated by in v

72 mus) and the most promising absorptivity for photodynamic therapy application, was tested as efficien

73 contrast generation settings, as well as its photodynamic therapy application.

74 Near-IR absorption, desired for potential photodynamic therapy applications, was not pursuable for

75 Oncolytic viral therapy and photodynamic therapy are potential therapies for inopera

76 nor light-induced medicinal chemistry (e.g., photodynamic therapy) are covered, even if metal complex

77 ession in cancer cells and susceptibility to photodynamic therapy based on their increased ability to

78 ood coloring agent and a photosensitizer for photodynamic therapy because of its antioxidant properti

79 atoses (AKs) is as effective as conventional photodynamic therapy but has the advantage of being almo

80 e ROS not only directly kills tumor cells by photodynamic therapy but stimulates the dimeric paclitax

81 f natural systems and integral components of photodynamic therapy, but their utilization is compromis

82 er enabled the realization of self-amplified photodynamic therapy by the regulation of Ppa release us

83 Photodynamic therapy can be an effective alternative for

84 cations, including therapeutic (photothermal/photodynamic therapy, chemotherapy and synergistic thera

85 is, including cryosurgery, ingenol mebutate, photodynamic therapy, colchicine, and 5-fluorouracil.

86 Photodynamic therapy combining nanotechnology has shown

87 Here we demonstrate a photodynamic therapy construct that integrates both a cy

88 enkov luminescence imaging and (2) Cherenkov-photodynamic therapy (CR-PDT) on cells could be achieved

89 -VEGF therapy increased from 60.3% to 72.7%, photodynamic therapy decreased from 12.8% to 5.3%, and t

90 Rose bengal- and riboflavin-mediated photodynamic therapy demonstrated complete growth inhibi

91 imaging and synergetic photothermal therapy/photodynamic therapy derived from the porphyrin-like moi

92 osensitizers into nanostructures can improve photodynamic therapy efficacy and the safety profile of

93 as photosynthesis, vision, photolithography, photodynamic therapy, etc., is yet to become a common to

94 on of photosensitizers is a key component of photodynamic therapy, exogenous photothermal contrast ag

95 re to sunlight and other patients undergoing photodynamic therapy experience similar pain, which can

96 e variety of potential applications, such as photodynamic therapy for accelerated drug screening, mag

97 therapy and artificial white light (AWL) LED photodynamic therapy for the treatment of AKs on the for

98 eporfin (VP), a light-activated drug used in photodynamic therapy for the treatment of choroidal neov

99 was 58 (28%) of 206 in the vascular-targeted photodynamic therapy group compared with 120 (58%) of 20

100 101 (49%) men in the vascular-targeted photodynamic therapy group had a negative prostate biops

101 tatitis (three [2%] in the vascular-targeted photodynamic therapy group vs one [<1%] in the active su

102 rious adverse event in the vascular-targeted photodynamic therapy group was retention of urine (15 pa

103 Photodynamic therapy has a 14%better chance of complete

104 Methyl aminolevulinate photodynamic therapy has been effective in 1 case but in

105 The non-invasive photodynamic therapy has been limited to treat superfici

106 for phototherapeutic interventions, such as photodynamic therapy, has transformed medicine and biolo

107 The combinational chemo- photodynamic therapy heavily suppresses tumor growth and

108 photodynamic therapy, named X-ray inducible photodynamic therapy, holds tremendous promise due to a

109 Daylight photodynamic therapy, however, requires dry and warm wea

110 The Microneedle Photodynamic Therapy II (MNPDT-II) study was a randomize

111 Photodynamic therapy in combination with antivascular en

112 lar endothelial growth factor or verteporfin photodynamic therapy in combination with systemic chemot

113 o examine the responses to vascular-targeted photodynamic therapy in mice with subcutaneous xenograft

114 d treatment with the possibility of combined photodynamic therapy in refractory cases.

115 Photodynamic therapy, in which malignant tissue is kille

116 interventions (argon laser photocoagulation, photodynamic therapy, intravitreal corticosteroids, and

117 TERPRETATION: Padeliporfin vascular-targeted photodynamic therapy is a safe, effective treatment for

118 Padeliporfin vascular-targeted photodynamic therapy is a safe, effective treatment for

119 Photodynamic therapy is the combination of non-toxic pho

120 Furthermore, photodynamic therapy is used to initiate the inflammator

121 iolet and visible light, and also to develop photodynamic therapy, it is important to resolve the mec

122 notherapy or combination IVB and verteporfin photodynamic therapy (IVB/PDT).

123 , 5% imiquimod cream, methyl aminolevulinate photodynamic therapy (MAL-PDT), or 0.015% ingenol mebuta

124 Photodynamic therapy may be an effective therapeutic opt

125 Photodynamic therapy may cause pain at the treatment sit

126 of X-rays instead of UV/Vis light to trigger photodynamic therapy, named X-ray inducible photodynamic

127 pecific interventions (acitretin, imiquimod, photodynamic therapy, nicotinamide, topical diclofenac,

128 bles can act as ideal miniature reactors for photodynamic therapy of cancer cells.

129 frared light, which has great implication in photodynamic therapy of deep-tissue cancers.

130 omedical applications is exemplified here as photodynamic therapy of malignancies.

131 l CPs are efficient photosensitizers for the photodynamic therapy of ras-driven cancers.

132 croneedles could be a promising approach for photodynamic therapy of skin tumors.

133 ng-guided synergistic radio-/X-ray inducible photodynamic therapy of tumors is reported.

134 bined with protoporphyrin IX (PpIX)-mediated photodynamic therapy on a variety of human pancreatic ca

135 gnosed as having exudative ARMD who received photodynamic therapy or anti-VEGF therapy compared with

136 radiotherapy with chemotherapy, gas therapy, photodynamic therapy, or immunotherapy.

137 uorescent probes and sensors, photouncaging, photodynamic therapy, or singlet-oxygen detection.

138 ffect compared with reovirus monotherapy and photodynamic therapy (p=0.042) with 100% cell death obse

139 otic lesions followed by aminolevulinic acid photodynamic therapy (PDT) 1 to 2 weeks later.

140 ing pigment (methylene blue - MB) to mediate photodynamic therapy (PDT) against Streptococcus mutans

141 ypyridyl complexes show great promise as new photodynamic therapy (PDT) agents.

142 rties were investigated for use as potential photodynamic therapy (PDT) agents.

143 development of 2 therapies: (1) verteporfin photodynamic therapy (PDT) and (2) anti-vascular endothe

144 evice has been developed to perform in vitro photodynamic therapy (PDT) and diagnostic assays for tre

145 e recently contributed to the progression of photodynamic therapy (PDT) and microbial photodynamic in

146 the design of transition metal complexes for photodynamic therapy (PDT) and photoactivated chemothera

147 ed with various therapy strategies including photodynamic therapy (PDT) and photothermal therapy (PTT

148 antigen presentation by enabling immunogenic photodynamic therapy (PDT) and promoting the maturation

149 The combination of photodynamic therapy (PDT) and radiation therapy (RT) mo

150 , presumably through the combined effects of photodynamic therapy (PDT) and released chemotherapy dru

151 um behavior, leading to efficient probes for photodynamic therapy (PDT) and stochastic optical recons

152 f increasing interest as photosensitizers in photodynamic therapy (PDT) and, more recently, for photo

153 Cationic antimicrobial peptides (CAMPs) and photodynamic therapy (PDT) are attractive tools to comba

154 inical experiments addressing the effects of photodynamic therapy (PDT) as an adjunct to conventional

155 This study investigates the effect of photodynamic therapy (PDT) as monotherapy during support

156 opportunities of NP imaging and therapy on a photodynamic therapy (PDT) based NP system that has been

157 namic therapy (SDT), which is different from photodynamic therapy (PDT) by the use of highly penetrat

158 Photodynamic therapy (PDT) can destroy local tumors and

159 we have found that addition of erlotinib to photodynamic therapy (PDT) can improve treatment respons

160 Photodynamic therapy (PDT) efficacy is limited by the ve

161 neration and exhibits significantly enhanced photodynamic therapy (PDT) efficacy on two colon cancer

162 Moreover, it could be shown that photodynamic therapy (PDT) elevates antitumor immune res

163 vitro, including both chemotherapy drugs and photodynamic therapy (PDT) for ovarian cancer.

164 The utilization of photodynamic therapy (PDT) for the treatment of various

165 Photodynamic therapy (PDT) has been applied in cancer tr

166 In recent years photodynamic therapy (PDT) has received widespread atten

167 Photodynamic therapy (PDT) holds great promise for cance

168 The viable use of photodynamic therapy (PDT) in cancer therapy has never b

169 for their potential as photosensitizers for photodynamic therapy (PDT) in P-glycoprotein (P-gp) expr

170 herapy in ancient texts and the discovery of photodynamic therapy (PDT) in the early 1900s, the landm

171 Continuous irradiation during photodynamic therapy (PDT) inevitably induces tumor hypo

172 Photodynamic therapy (PDT) involves the intravenous admi

173 Photodynamic therapy (PDT) is a clinically approved anti

174 Photodynamic therapy (PDT) is a clinically approved ther

175 Photodynamic therapy (PDT) is a light-based treatment mo

176 Photodynamic therapy (PDT) is a new strategy for treatin

177 Photodynamic therapy (PDT) is a promising approach to tr

178 Photodynamic therapy (PDT) is a promising cancer treatme

179 Photodynamic therapy (PDT) is a promising treatment stra

180 Photodynamic therapy (PDT) is a technique developed to t

181 Photodynamic therapy (PDT) is an alternative treatment f

182 Photodynamic therapy (PDT) is an approved modality for t

183 Photodynamic therapy (PDT) is an effective and cosmetica

184 Photodynamic therapy (PDT) is an effective anticancer pr

185 Photodynamic therapy (PDT) is an efficacious treatment f

186 Photodynamic therapy (PDT) is an important cancer treatm

187 Photodynamic therapy (PDT) is an important clinically re

188 reatment of hypoxic tumors, oxygen-dependent photodynamic therapy (PDT) is considerably limited.

189 Photodynamic therapy (PDT) is generally based on the gen

190 Photodynamic therapy (PDT) is used extensively to treat

191 Photodynamic therapy (PDT) is widely used to treat diver

192 Photodynamic therapy (PDT) is widely used to treat non-m

193 With the knowledge that the dominant photodynamic therapy (PDT) mechanism of 1a (WST09) switc

194 ial of this conjugate as photosensitizer for photodynamic therapy (PDT) of cancers overexpressing the

195 great potential as nanophotosensitizers for photodynamic therapy (PDT) owing to their high photosens

196 Singlet oxygen sensitized photodynamic therapy (PDT) relies on the concentration o

197 he resulting RB-C(KLAKLAK)(2) conjugate as a photodynamic therapy (PDT) sensitizer.

198 clinically approved intervention for cancer, photodynamic therapy (PDT) still suffers from limitation

199 Although photodynamic therapy (PDT) takes advantage of the spatia

200 are employed to deliver photosensitizers for photodynamic therapy (PDT) through the enhanced penetrat

201 orescence for image-guided surgery (IGS) and photodynamic therapy (PDT) to resect and ablate cancer c

202 treatment, it allowed delivery of selective photodynamic therapy (PDT) to the cancerous tissues, wit

203 These vulnerable cells are subjected to photodynamic therapy (PDT) treatment in the presence of

204 Furthermore, immunogenic ZnP@pyro photodynamic therapy (PDT) treatment sensitizes tumors t

205 e entrapped agents that harnesses sub-lethal photodynamic therapy (PDT) using a photosensitiser that

206 chanisms how the efficacy of photofrin based photodynamic therapy (PDT) was enhanced by miR-99a trans

207 racellular localization and cell response to photodynamic therapy (PDT) were analyzed in MCF10A norma

208 d visual outcomes using combination standard photodynamic therapy (PDT) with intravitreal ranibizumab

209 integration of fluorescence imaging (FL) and photodynamic therapy (PDT) with positron emission tomogr

210 Photodynamic therapy (PDT) with protoporphyrin IX (PpIX)

211 nstrate that benzoporphyrin derivative-based photodynamic therapy (PDT), a photochemical cytotoxic mo

212 Photodynamic therapy (PDT), a treatment that uses a phot

213 f cancer and dermatological diseases through photodynamic therapy (PDT), and advanced materials for e

214 , 0.09, and 0.07 LogMAR in the no-treatment, photodynamic therapy (PDT), bevacizumab, and ranibizumab

215 rossing (ISC) are highly promising for smart photodynamic therapy (PDT), but achieving this goal rema

216 rates cytotoxic singlet oxygen ((1)O(2)) for photodynamic therapy (PDT), but also triggers a spontane

217 In photodynamic therapy (PDT), cells are impregnated with a

218 additional limitations of porphyrin-mediated photodynamic therapy (PDT), including low depths of tiss

219 ent procedures, such as laser irradiation or photodynamic therapy (PDT), may provide some additional

220 each clinical treatment tool (chemotherapy, photodynamic therapy (PDT), radiotherapy (RT)) by contro

221 In the case of photodynamic therapy (PDT), two-photon absorption combin

222 In order to promote the development of photodynamic therapy (PDT), undesired side effects like

223 ptake of photosensitizers by cancer cells in photodynamic therapy (PDT), we designed a smart plasma m

224 Photodynamic therapy (PDT), wherein light sensitive non-

225 PCI is founded upon the principle of photodynamic therapy (PDT), which uses light to activate

226 ent protoporphyrin IX (PPIX) accumulation in photodynamic therapy (PDT).

227 et oxygen ((1) O2 ) is of great interest for photodynamic therapy (PDT).

228 ce lifetime microscopy (2PLM) and two-photon photodynamic therapy (PDT).

229 ture-activity relationships for their use in photodynamic therapy (PDT).

230 available and urgently desired for antitumor photodynamic therapy (PDT).

231 CP@pyrolipid) for effective chemotherapy and photodynamic therapy (PDT).

232 ing because (1)O2 plays an important role in photodynamic therapy (PDT).

233 or as the shell for potential application in photodynamic therapy (PDT).

234 erapy (PTT), and light to singlet oxygen for photodynamic therapy (PDT).

235 n investigated as photosensitizers (PSs) for photodynamic therapy (PDT).

236 at are illuminated, and this is the basis of photodynamic therapy (PDT).

237 thus may hold promise as photosensitizers in photodynamic therapy (PDT).

238 a photosensitizer that acts as an agent for photodynamic therapy (PDT).

239 aptive immunity following treatments such as photodynamic therapy (PDT).

240 tment protocols, including dental lasers and photodynamic therapy (PDT).

241 l process for fundamental photochemistry and photodynamic therapy (PDT).

242 age biological tissue, which is exploited in photodynamic therapy (PDT).

243 spatially-targeted cytotoxic therapy called photodynamic therapy (PDT).

244 intratumoral near-infrared (NIR) two-photon photodynamic therapy (PDT).

245 injections with bevacizumab; ranibizumab; or photodynamic therapy (PDT).

246 MRI contrasting agents, and sensitizers for photodynamic therapy (PDT); and more recently as models

247 (MARINA), or were randomized to verteporfin photodynamic therapy (PDT; n=143), 0.3-mg ranibizumab mo

248 Antibody-based photodynamic therapy-photoimmunotherapy (PIT)-is an idea

249 atform for the high-throughput assessment of photodynamic therapy photosensitizer (PDT) efficacy on E

250 addition, light activation has potential in photodynamic therapy, photothermal therapy, radiotherapy

251 , which is used as an antimicrobial agent in photodynamic therapy, potentiates tellurite toxicity.

252 gated as cytotoxic agents and inhibitors, in photodynamic therapy, radiation therapy, drug/gene deliv

253 rapies were identified: electrochemotherapy, photodynamic therapy, radiotherapy, intralesional therap

254 Photodynamic therapy regimens, which use light-activated

255 es applications in bioimaging and diagnosis, photodynamic therapy regimes, in addition to photovoltai

256 Photodynamic therapy-related complications included intr

257 Two eyes received photodynamic therapy rescue during subsequent follow-up

258 Reovirus with PpIX-mediated photodynamic therapy resulted in a significantly increas

259 vely killing beta-cells by receptor-targeted photodynamic therapy (rtPDT) with exendin-4-IRDye700DX,

260 tionic and anionic phthalocyanines (Pcs) for photodynamic therapy suggest systematically significant

261 Photodynamic therapy that uses photosensitizers which on

262 d radical ions (Type I reaction); whereas in photodynamic therapy, the tumor destruction is mainly ca

263 , photoreformation, photoredox catalysis and photodynamic therapy, they are being developed in surpri

264 hogonal reactions as an original strategy in photodynamic therapy to achieve conditional phototoxicit

265 s oncolytic viral therapy with PpIX-mediated photodynamic therapy to treat pancreatic cancer.

266 scular endothelial growth factor injections, photodynamic therapy, topical dorzolamide, oral dosing o

267 Photodynamic therapy using an AWL source was as effectiv

268 Photodynamic therapy using porfimer (P-PDT) improves pal

269 Daylight photodynamic therapy using topical methyl 5-aminolevulin

270 Photodynamic therapy using verteporfin at a dose of 6 mg

271 on with Photodynamic Therapy; Verteporfin in Photodynamic Therapy; VEGF Inhibition Study in Ocular Ne

272 ent of Age-Related Macular Degeneration with Photodynamic Therapy; Verteporfin in Photodynamic Therap

273 anic framework, Zr-TBB, for highly effective photodynamic therapy via both type I and type II mechani

274 vitreal anti-VEGF injection; (3) verteporfin photodynamic therapy (vPDT); or (4) laser photocoagulati

275 xamine the hypothesis that vascular-targeted photodynamic therapy (VTP) with WST11 and clinically rel

276 The effect of adding reovirus after photodynamic therapy was also assessed.

277 Photodynamic therapy was associated with improved VA and

278 Next, the potential of SCPNs for photodynamic therapy was evaluated.

279 Their photosensitizing potential for photodynamic therapy was investigated in an in vitro mod

280 The potential of PPIX for photodynamic therapy was tested in vivo.

281 Vascular-targeted photodynamic therapy was well tolerated.

282 rcumvent the limitations of chemotherapy and photodynamic therapy, we have engineered a robust and sm

283 s as photosensitizers for oxygen sensing and photodynamic therapy, we investigated the potential beta

284 ects of reovirus combined with PpIX-mediated photodynamic therapy were analysed in methylthiazoltetra

285 Laser therapy and photodynamic therapy were not applicable due to the exte

286 Anti-VEGF agents and photodynamic therapy were the only interventions identif

287 omy, cryotherapy, laser photocoagulation, or photodynamic therapy, were excluded from the analysis.

288 in rare diseases, such as porphyrias, and in photodynamic therapy where short-term toxicity is intend

289 itization represents a promising approach in photodynamic therapy where the design of the active phot

290 Verteporfin (VP) was first used in Photodynamic therapy, where a non-thermal laser light (6

291 photothermal therapy and porphyrin-mediated photodynamic therapy which results in complete tumor eli

292 mour cells with low or no PTEN expression to photodynamic therapy, which is based on the ability of p

293 Two main approaches are available: photodynamic therapy, which results in localized chemica

294 Chemophototherapy (CPT) merges photodynamic therapy with chemotherapy and can substanti

295 Photodynamic therapy with microneedle pretreatment at a

296 Photodynamic therapy with the construct was successful i

297 Photodynamic therapy with verteporfin is an effective ou

298 X-ray-induced photodynamic therapy (X-PDT) combines both the advantage

299 ine) and their applications in X-ray-induced photodynamic therapy (X-PDT) of colon cancer.

300 to achieve efficient low-dose X-ray-induced photodynamic therapy (X-PDT) with negligible side effect